Drug Topics reports providers prescribing unapproved retatrutide for weight loss
Retatrutide remains an investigational Eli Lilly candidate, yet the report describes prescribing occurring at a rate it calls alarming.
DO
By Daniel Okafor · Regulatory Correspondent
Jun 10 03:00 ETSource: Drug Topics
The wire
- 01Drug Topics reports that some providers are prescribing unapproved retatrutide for weight loss.
- 02Dispensing an investigational incretin outside trials exposes pharmacies, prescribers and telehealth operators to sourcing and liability risk.
- 03The report does not establish the source of the product or the volume involved, both of which bear on regulatory exposure.
From the source
Read at drugtopics.comSome Providers Prescribe Unapproved Retatrutide for Weight Loss at Alarming Rate